Human epidermal growth factor receptor 2 negative breast cancer (HER2-BC) is ineffective in anti-endocrine therapy and targeted therapy with HER2 gene positive because of the lack of corresponding receptor expression, with high invasiveness, high recurrence risk, poor prognosis and high metastasis rate,[1] and among HER2 negative breast cancers, triple negative breast cancer (TNBC) is the most pessimistic one. Here, ERBB2 is linked to triple-negative breast carcinoma.